Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome
Kelly D. Flemming,Helen Kim,Stephanie Hage,Jay Mandrekar,Serena Kinkade,Romuald Girard,Michel Torbey,Judy Huang,John Huston,Yunhong Shu,Giuseppe Lanzino,Reed Selwyn,Blaine Hart,Marc Mabray,James Feghali,Haris I. Sair,Jared Narvid,Janine M. Lupo,Justine Lee,Agnieszka Stadnik,Roberto J. Alcazar-Felix,Robert Shenkar,Karen Lane,Nichole McBee,Kevin Treine,Noeleen Ostapkovich,Ying Wang,Richard Thompson,James I. Koenig,Timothy Carroll,Daniel Hanley,Issam Awad
DOI: https://doi.org/10.1161/strokeaha.123.044068
IF: 10.17
2023-12-23
Stroke
Abstract:Stroke, Volume 55, Issue 1, Page 22-30, January 1, 2024. BACKGROUND:Cerebral cavernous malformation with symptomatic hemorrhage (SH) are targets for novel therapies. A multisite trial-readiness project (https://www.clinicaltrials.gov; Unique identifier: NCT03652181) aimed to identify clinical, imaging, and functional changes in these patients.METHODS:We enrolled adult cerebral cavernous malformation patients from 5 high-volume centers with SH within the prior year and no planned surgery. In addition to clinical and imaging review, we assessed baseline, 1- and 2-year National Institutes of Health Stroke Scale, modified Rankin Scale, European Quality of Life 5D-3 L, and patient-reported outcome-measurement information system, Version 2.0. SH and asymptomatic change rates were adjudicated. Changes in functional scores were assessed as a marker for hemorrhage.RESULTS:One hundred twenty-three, 102, and 69 patients completed baseline, 1- and 2-year clinical assessments, respectively. There were 21 SH during 178.3 patient years of follow-up (11.8% per patient year). At baseline, 62.6% and 95.1% of patients had a modified Rankin Scale score of 1 and National Institutes of Health Stroke Scale score of 0 to 4, respectively, which improved to 75.4% (P=0.03) and 100% (P=0.06) at 2 years. At baseline, 74.8% had at least one abnormal patient-reported outcome-measurement information system, Version 2.0 domain compared with 61.2% at 2 years (P=0.004). The most common abnormal European Quality of Life 5D-3 L domains were pain (48.7%), anxiety (41.5%), and participation in usual activities (41.4%). Patients with prospective SH were more likely than those without SH to display functional decline in sleep, fatigue, and social function patient-reported outcome-measurement information system, Version 2.0 domains at 2 years. Other score changes did not differ significantly between groups at 2 years. The sensitivity of scores as an SH marker remained poor at the time interval assessed.CONCLUSIONS:We report SH rate, functional, and patient-reported outcomes in trial-eligible cerebral cavernous malformation with SH patients. Functional outcomes and patient-reported outcomes generally improved over 2 years. No score change was highly sensitive or specific for SH and could not be used as a primary end point in a trial.
peripheral vascular disease,clinical neurology